Tools for Practice Outils pour la pratique

#317 Antihistamines for allergic rhinosinusitis: ‘Achoo’sing the right treatment

Do oral antihistamines improve symptoms in adults with allergic rhinosinusitis?

Oral antihistamines reduce rhinosinusitis symptoms by ~10-30% versus placebo over 2-12 weeks. Individual antihistamines appear to have comparable efficacy. More patients attain moderate or better improvement with intranasal corticosteroids (~50%) versus antihistamines (~30%). There appears to be no meaningful differences between antihistamines and leukotriene receptor antagonists or in adding antihistamines to intranasal corticosteroids.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • Results statistically significant unless otherwise noted.
  • Antihistamines versus placebo:
    • Systematic review [7 randomized controlled trials (RCTs), 639 patients] of antihistamines versus placebo over 2-12 weeks.1
      • Patient-rated nasal obstruction score (scale 0-3, higher worse), baseline=1.65: Placebo improved symptoms 16% and antihistamines 48%.
    • Systematic review (5 RCTs, 3329 patients) of bilastine (newer antihistamine) versus placebo over 1-12 weeks.2
      • Total symptom score effect size=0.28, similar to improving symptoms 10-16% over placebo.3
    • Other systematic reviews found simiar.4-6
  • Antihistamines versus antihistamines:
    • Systematic reviews showed no statistical or clinical differences in Total or Nasal Symptom Scores between antihistamines.2,7
  • Antihistamines and other agents:
    • Two systematic reviews (5-16 RCTs, 990-2267 patients) compare intranasal corticosteroids to antihistamines over 2-8 weeks.8,9 Total nasal symptom scores improved more with intranasal corticosteroids (51%) versus antihistamines (31%).
      • Proportion attaining moderate control or better10 was higher with intranasal steroids (78%) versus antihistamines (58%), number needed to treat=5.
    • Systematic review (13 RCTs, 5066 patients) of antihistamines plus intranasal corticosteroids versus intranasal corticosteroids alone over 2-6 weeks.11
      • Antihistamine did not add clinically meaningful benefit.
      • Other systematic reviews found similar.12-13
    • Two systematic reviews (9-14 mixed-design studies, 4458-5781 patients) of antihistamines versus leukotriene receptor antagonist over 1-12 weeks: No clinically meaningful differences.14,15
  • Limitations: Too many to list but include per protocol analysis, incorrect meta-analysis techniques, negative studies not published, and scales defined inconsistently.1,7,11,12,15
  • Most antihistamines and many intranasal corticosteroids are available over-the-counter.
  • Adverse event data is infrequently reported, inconsistent, and pooled statistics are generally not clinically interpretable.16 Versus Placebo:
    • Diphenhydramine mild/moderately more sedating (effect size=0.36).
    • Second-generation antihistamines slightly more sedating (effect size=0.14).16
    • Some antihistamines may have less sedation: Fexofenadine versus other second-generation (statistic uninterpretable)17 or bilastine (3%) versus cetirizine (7%).2

Linda Hernandez Lopez August 6, 2022

What is the recommended duration of Tx for intranasal corticosteroids?

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Betsy Thomas BSc. Pharm
  • Antony Train MBChB MSc CCFP
  • G. Michael Allan MD CCFP

1. Hore I, Georgalas C, Scadding G. Clin Exp Allergy. 2005 Feb; 35(2):207-12. doi: 10.1111/j.1365-2222.2005.02159.x. Erratum in: Clin Exp Allergy. 2005 Apr; 35(4):547.

2. Singh Randhawa A, Mohd Noor N, Md Daud MK, et al. Front Pharmacol. 2022 Jan 10; 12:731201.

3. Bachert C, Kuna P, Sanquer F, et al. Allergy. 2009 Jan; 64(1):158-65.

4. Canonica GW, Tarantini F, Compalati E, et al. Allergy. 2007 Apr; 62(4):359-66.

5. Compalati E, Baena-Cagnani R, Penagos M, et al. Arch Allergy Immunol. 2011; 156(1):1-15.

6. Mösges R, König V, Köberlein J. Allergol Int. 2011 Dec; 60(4):541-6.

7. Xiao J, Wu WX, Ye YY, et al. Am J Ther. 2016 Nov/Dec; 23(6):e1568-e1578.

8. Juel-Berg N, Darling P, Bolvig J, et al. Am J Rhinol Allergy. 2017 Jan 9; 31(1):19-28.

9. Weiner JM, Abramson MJ, Puy RM. BMJ. 1998 Dec 12; 317(7173):1624-9.

10. Schoenwetter W, Lim J. Clin Ther. 1995 May-Jun; 17(3):479-92

11. Du K, Qing H, Zheng M, et al. Ann Allergy Asthma Immunol. 2020 Nov; 125(5):589-596.e3

12. Feng S, Fan Y, Liang Z, et al. Eur Arch Otorhinolaryngol. 2016 Nov; 273(11):3477-3486.

13. Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, et al. Int Forum Allergy Rhinol. 2018 Oct; 8(10):1083-1092.

14. Xu Y, Zhang J, Wang J. PLoS One. 2014 Nov 10; 9(11):e112815.

15. Feng Y, Meng YP, Dong YY, et al. Allergy Asthma Clin Immunol. 2021 Jun 29; 17(1):62.

16. Bender BG, Berning S, Dudden R, et al. J Allergy Clin Immunol. 2003 Apr; 111(4):770-6.

17. Huang CZ, Jiang ZH, Wang J, et al. BMC Pharmacol Toxicol. 2019 Nov 29; 20(1):72.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.